European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

From my colleague Andrew Joseph: After a bumpy road, Eisai and Biogen’s Alzheimer’s therapy Leqembi has won approval in ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...